AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 397017 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine and Physical training
Number of subjects: 24
Study 30990260 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg daily
Number of subjects: 4401
Study 30990260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4401
Study 28772310 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype questionnaire for self-assessment of ear disease risk
Number of subjects: 307
Study 28772310 — intervention group
Group type: COMPARATOR
Intervention: Control group with age- or noise-related hearing loss
Number of subjects: 307
Study 25908001 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-energy SLT treatment (270°)
Number of subjects: 45
Study 25908001 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-threshold energy SLT treatment (360°)
Number of subjects: 45
Study 25168375 — intervention group
Group type: EXPERIMENTAL
Intervention: STAND-SIT condition (interchanging between standing and seated work posture every 30 min using an electric, height-adjustable workstation)
Number of subjects: 23
Study 25168375 — intervention group
Group type: COMPARATOR
Intervention: SIT condition (seated work posture)
Number of subjects: 23
Study 25168375 — intervention group
Group type: EXPERIMENTAL
Intervention: STAND-SIT condition
Number of subjects: 23
Study 25168375 — intervention group
Group type: COMPARATOR
Intervention: SIT condition
Number of subjects: 23
Study 21402724 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness Recovery Action Planning (WRAP)
Number of subjects: 519
Study 21402724 — intervention group
Group type: COMPARATOR
Intervention: Usual care (wait-list control)
Number of subjects: 519
Study 19168173 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific elements of the target event
Number of subjects: 49
Study 19168173 — intervention group
Group type: COMPARATOR
Intervention: Generic elements of the target event
Number of subjects: 49
Study 17764564 — intervention group
Group type: EXPERIMENTAL
Intervention: ChewFree.com program for smokeless tobacco cessation
Number of subjects: 0
Study 17764564 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers' Health Improvement Program (SHIP) for smoking cessation
Number of subjects: 0
Study 15151720 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification in flexible micropipettes by immersion in LN2 (VLN)
Number of subjects: 429
Study 15151720 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmable rate freezing (PR)
Number of subjects: 429
Study 15151720 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification in flexible micropipettes by immersion in super-cooled liquid nitrogen (VSC)
Number of subjects: 429
Study 15151720 — intervention group
Group type: COMPARATOR
Intervention: Control (not refrozen)
Number of subjects: 429
Study 11163812 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU rFSH (n = 146)
Number of subjects: 345
Study 11163812 — intervention group
Group type: COMPARATOR
Intervention: 200 IU rFSH (n = 151)
Number of subjects: 345
Study 11163812 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 IU rFSH (n = 24)
Number of subjects: 345
Study 11163812 — intervention group
Group type: COMPARATOR
Intervention: 400 IU rFSH (n = 24)
Number of subjects: 345
Study 11163812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of rFSH
Number of subjects: 345
Study 11163812 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous administration of rFSH
Number of subjects: 345
Study 11163812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular 150 IU rFSH
Number of subjects: 345
Study 9884789 — intervention group
Group type: EXPERIMENTAL
Intervention: NCAA Division I, II, III athletes with ACL injury
Number of subjects: 0
Study 9884789 — intervention group
Group type: COMPARATOR
Intervention: NCAA Division I, II, III athletes without ACL injury
Number of subjects: 0
Study 8021633 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of alcohol (blood concentration of 96mg/dL)
Number of subjects: 40
Study 8021633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2342217 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1% tretinoin
Number of subjects: 6
Study 2342217 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 6
Study 211984 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 17
Study 211984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 30953936 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collected within procedural registries and claims databases
Number of subjects: 0
Study 30953936 — intervention group
Group type: COMPARATOR
Intervention: Trial-ascertained variables and endpoints
Number of subjects: 0
Study 28723976 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressively trained frequency range (300-600 Hz or 3000-6000 Hz) with gradually increasing similarity of sounds during training.
Number of subjects: 0
Study 28723976 — intervention group
Group type: COMPARATOR
Intervention: Constant stimulus similarity throughout training in one frequency range.
Number of subjects: 0
Study 26002686 — intervention group
Group type: EXPERIMENTAL
Intervention: GCCM (Mediterranean diet-based cooking and nutrition curriculum)
Number of subjects: 27
Study 26002686 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 23795805 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone/everolimus (P/EVL)
Number of subjects: 23
Study 23795805 — intervention group
Group type: COMPARATOR
Intervention: prednisolone/cyclosporine A (P/CsA)
Number of subjects: 23
Study 21471763 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-pursestring stapled hemorrhoidopexy
Number of subjects: 200
Study 19622887 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A (Dysport)
Number of subjects: 127
Study 19622887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 19622887 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A (high-dose)
Number of subjects: 127
Study 19622887 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A (other doses)
Number of subjects: 127
Study 19023175 — intervention group
Group type: EXPERIMENTAL
Intervention: MHACL intervention program
Number of subjects: 1071
Study 19023175 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1071
Study 15364332 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs
Number of subjects: 2033
Study 11216966 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy
Number of subjects: 3712
Study 11216966 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 3712
Study 9532987 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean section delivery at 38 weeks
Number of subjects: 339
Study 9532987 — intervention group
Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 339
Study 7807627 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole orally for 10 days
Number of subjects: 151
Study 7807627 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine penicillin G intramuscularly for 10 days
Number of subjects: 151
Study 7807627 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathin penicillin G combined with procaine penicillin G as a single dose intramuscularly
Number of subjects: 151
Study 2692189 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole, 400 mg (single dose)
Number of subjects: 102
Study 2692189 — intervention group
Group type: COMPARATOR
Intervention: Mebendazole, 600 mg (single dose)
Number of subjects: 102
Study 811102 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release nitroglycerin (2.6 mg tablets administered three times daily)
Number of subjects: 53
Study 11694668 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized treadmill intervention (5 days per week, 8 minutes per day)
Number of subjects: 30
Study 11694668 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional physical therapy at least every other week)
Number of subjects: 30
Study 31454023 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine
Number of subjects: 0
Study 31454023 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29503110 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV10 vaccine (GSK)
Number of subjects: 30527
Study 29503110 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B/A vaccine (control)
Number of subjects: 30527
Study 27169640 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-month multi-component intervention including policy changes to food served, employee wellness initiatives, classroom activities promoting physical activity and healthy eating, and training and technical assistance.
Number of subjects: 23
Study 24751432 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone (BUP)
Number of subjects: 1269
Study 24751432 — intervention group
Group type: COMPARATOR
Intervention: Methadone (MET)
Number of subjects: 1269
Study 24751432 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BUP and MET
Number of subjects: 1269
Study 26845812 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Kangaroo Mother Care (KMC) for 8 hours per day
Number of subjects: 166
Study 26845812 — intervention group
Group type: COMPARATOR
Intervention: Control (incubators or cots)
Number of subjects: 166
Study 26845812 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Kangaroo Mother Care (KMC)
Number of subjects: 166
Study 26845812 — intervention group
Group type: COMPARATOR
Intervention: Control (regular care)
Number of subjects: 166
Study 20056760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (4000 IU/d for 1 month, then 2000 IU/d)
Number of subjects: 47
Study 20056760 — intervention group
Group type: COMPARATOR
Intervention: Doxercalciferol (1 microg/d)
Number of subjects: 47
Study 17107982 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbruggen scoring method
Number of subjects: 105
Study 17107982 — intervention group
Group type: EXPERIMENTAL
Intervention: Kellgren-Lawrence (KL) scoring method
Number of subjects: 105
Study 17107982 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallman scoring method
Number of subjects: 105
Study 17107982 — intervention group
Group type: EXPERIMENTAL
Intervention: Global scoring method
Number of subjects: 105
Study 15842248 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-setting calcium hydroxide (Ca(OH)2) cement placed in the root canal system, with 22 teeth restored following conditioning of the access cavity margins and 8 teeth having the margins cleaned with a hand excavator.
Number of subjects: 62
Study 15842248 — intervention group
Group type: COMPARATOR
Intervention: Glass-ionomer cement (GIC) restoration following drying of the canal and placement of a cotton wool pledget.
Number of subjects: 62
Study 12140638 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium level training (group B, n = 13)
Number of subjects: 27
Study 12140638 — intervention group
Group type: COMPARATOR
Intervention: Easy level training (group A, n = 14)
Number of subjects: 27
Study 9584247 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone intraocular lens (IOL) through a 3.2 mm incision
Number of subjects: 200
Study 9584247 — intervention group
Group type: COMPARATOR
Intervention: Poly(methyl methacrylate) (PMMA) IOL through a 5.5 mm incision
Number of subjects: 200
Study 8609194 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneutralization
Number of subjects: 621
Study 8609194 — intervention group
Group type: COMPARATOR
Intervention: Western blot
Number of subjects: 621
Study 2672899 — intervention group
Group type: EXPERIMENTAL
Intervention: iv caffeine 10 mg/kg
Number of subjects: 32
Study 2672899 — intervention group
Group type: COMPARATOR
Intervention: iv saline (Control)
Number of subjects: 32
Study 1164878 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins and anabolic steroid clostebol (Steranabol)
Number of subjects: 66
Study 1164878 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 66
Study 31975209 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin application in the wound
Number of subjects: 113
Study 31975209 — intervention group
Group type: COMPARATOR
Intervention: No vancomycin application
Number of subjects: 113
Study 29186635 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Patient Education (COPE) intervention
Number of subjects: 0
Study 29186635 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25638752 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-peptides plus TLR agonists
Number of subjects: 0
Study 25638752 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive design for identifying optimal treatment strategy
Number of subjects: 0
Study 25638752 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation studies
Number of subjects: 0
Study 24355659 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose iterative (FDI) image reconstruction
Number of subjects: 100
Study 24355659 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose iterative (HDI) image reconstruction
Number of subjects: 100
Study 24355659 — intervention group
Group type: COMPARATOR
Intervention: Full-dose standard (FDS) image reconstruction
Number of subjects: 100
Study 21945081 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose bupivacaine
Number of subjects: 105
Study 21945081 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bupivacaine
Number of subjects: 105
Study 21945081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 19541736 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental-load exercise
Number of subjects: 18
Study 19541736 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant-load exercise
Number of subjects: 18
Study 19541736 — intervention group
Group type: COMPARATOR
Intervention: Inhaled albuterol (400 microg)
Number of subjects: 18
Study 18000778 — intervention group
Group type: EXPERIMENTAL
Intervention: IEN+rhGH
Number of subjects: 48
Study 18000778 — intervention group
Group type: COMPARATOR
Intervention: IEN
Number of subjects: 48
Study 15462191 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPK gene molecular analysis in DM patients
Number of subjects: 31
Study 15462191 — intervention group
Group type: COMPARATOR
Intervention: DMPK gene molecular analysis in controls
Number of subjects: 31
Study 15462191 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of lymphocyte and muscle tissue DNA in one DM patient
Number of subjects: 31
Study 11730442 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aptiganel (5-mg bolus followed by 0.75 mg/h for 12 hours; n = 214)
Number of subjects: 628
Study 11730442 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aptiganel (3-mg bolus followed by 0.5 mg/h for 12 hours; n = 200)
Number of subjects: 628
Study 11730442 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 214)
Number of subjects: 628
Study 8998158 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrin scintigraphy
Number of subjects: 268
Study 8998158 — intervention group
Group type: COMPARATOR
Intervention: Contrast venography
Number of subjects: 268
Study 8081045 — intervention group
Group type: EXPERIMENTAL
Intervention: C + R (chemotherapy with methotrexate, chlorambucil, vincristine, and cisplatin, given every 3 weeks)
Number of subjects: 151
Study 8081045 — intervention group
Group type: COMPARATOR
Intervention: R (radiotherapy only, 50 Gy in the pelvis with a boost by external irradiation of the brachytherapy, cumulative dose of 68 Gy)
Number of subjects: 151
Study 8081045 — intervention group
Group type: EXPERIMENTAL
Intervention: C + R
Number of subjects: 151
Study 8081045 — intervention group
Group type: COMPARATOR
Intervention: R
Number of subjects: 151
Study 3119022 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal episiotomy (51%)
Number of subjects: 674
Study 3119022 — intervention group
Group type: COMPARATOR
Intervention: Restrictive episiotomy (10%)
Number of subjects: 674
Study 29575526 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐42165279 (oral selective FAAH inhibitor)
Number of subjects: 0
Study 28723746 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 60
Study 28723746 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 60
Study 28723746 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation control group
Number of subjects: 60
Study 26033499 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional therapy (LRT) combined with arsenic trioxide (As2 O3) at 10 mg/d for 4 courses (21 days per course) with a 2-week interval between courses
Number of subjects: 125
Study 26033499 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional therapy (LRT) combined with arsenic trioxide (As2 O3)
Number of subjects: 125
Study 26033499 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B) receiving only transarterial chemoembolization
Number of subjects: 125
Study 24249851 — intervention group
Group type: EXPERIMENTAL
Intervention: Written and verbal feedback (third-year students in endocrinology class)
Number of subjects: 3
Study 24249851 — intervention group
Group type: EXPERIMENTAL
Intervention: Written feedback only (third-year students in endocrinology class)
Number of subjects: 3
Study 24249851 — intervention group
Group type: COMPARATOR
Intervention: No feedback (second-year students in cardiology class)
Number of subjects: 3
Study 21570485 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT intervention
Number of subjects: 7
Study 21570485 — intervention group
Group type: COMPARATOR
Intervention: Telephone support provided by NHS Direct Health Advisors
Number of subjects: 7
Study 21570485 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) control
Number of subjects: 7
Study 18308112 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemohormonal therapy (complete androgen blockage, docetaxel 70 mg/m2 on day 2, estramustine 280 mg three times daily on days 1 to 5 every 21 days) before radical prostatectomy.
Number of subjects: 22
Study 16799983 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 10 mg once daily
Number of subjects: 480
Study 16799983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 12542507 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a 30 mcg intramuscularly once weekly for 2 years
Number of subjects: 96
Study 11059882 — intervention group
Group type: EXPERIMENTAL
Intervention: Type B (spacing filaments external to the fibers)
Number of subjects: 18
Study 11059882 — intervention group
Group type: EXPERIMENTAL
Intervention: Type C (fibers waved to give Moiré structure)
Number of subjects: 18
Study 11059882 — intervention group
Group type: COMPARATOR
Intervention: Type A (standard fiber bundle)
Number of subjects: 18
Study 9298051 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% topical ketorolac
Number of subjects: 118
Study 9298051 — intervention group
Group type: COMPARATOR
Intervention: 0.03% topical flurbiprofen
Number of subjects: 118
Study 8289094 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy (HF)
Number of subjects: 108
Study 8289094 — intervention group
Group type: COMPARATOR
Intervention: Conventionally Fractionated Radiotherapy (CFR)
Number of subjects: 108
Study 2880218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin therapy
Number of subjects: 25
Study 2880218 — intervention group
Group type: COMPARATOR
Intervention: DST alone
Number of subjects: 25
Study 2880218 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparous patients or those with over 10 third-party transfusions
Number of subjects: 25
Study 2880218 — intervention group
Group type: EXPERIMENTAL
Intervention: DST pretreated transplants
Number of subjects: 25
Study 31987113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavacurcumin, Eicosapentaenoic acid (Omega-3s), Astaxanthin and Gamma-linoleic acid (Omega-6) (CEAG)
Number of subjects: 80
Study 31987113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 28762592 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructans
Number of subjects: 20
Study 28762592 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 20
Study 27475455 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Cross-Body Stretch (MCS)
Number of subjects: 24
Study 27475455 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Sleeper Stretch (MSS)
Number of subjects: 24
Study 24916615 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic Tool to Reduce Inappropriate Prescribing (STRIP)
Number of subjects: 106
Study 24916615 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-STRIP)
Number of subjects: 106
Study 22506537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine 20 mg/dimenhydrinate 40 mg (fixed combination)
Number of subjects: 62
Study 22506537 — intervention group
Group type: COMPARATOR
Intervention: Betahistine 12 mg
Number of subjects: 62
Study 20409427 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 30
Study 20409427 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration
Number of subjects: 30
Study 18525263 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 307
Study 18525263 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes simplex virus type 2 shedding
Number of subjects: 307
Study 18525263 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes simplex virus type 2 shedders
Number of subjects: 307
Study 15725188 — intervention group
Group type: COMPARATOR
Intervention: No egg
Number of subjects: 41
Study 15725188 — intervention group
Group type: EXPERIMENTAL
Intervention: Half a cooked egg
Number of subjects: 41
Study 15725188 — intervention group
Group type: EXPERIMENTAL
Intervention: One cooked egg
Number of subjects: 41
Study 15725188 — intervention group
Group type: EXPERIMENTAL
Intervention: One raw egg
Number of subjects: 41
Study 11673338 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF, Molgramostim) 40 microg intracoronary injection followed by 10 microg/kg subcutaneous for 2 weeks
Number of subjects: 21
Study 11673338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21